Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 701–800 of 1,640
van der Kooij, M. A., Masana, M., Rust, M. B., & Müller, M. B. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.12.001 · Cited by 24
Ni, S., Huang, H., He, D., Chen, H., Wang, C., Zhao, X., Chen, X., Cui, W., Zhou, W., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14670 · Cited by 24
Targeting the Neuronal Activity of Prefrontal Cortex: New Directions for the Therapy of Depression
Zhou, X., Bao, W.-D., Liu, D., & Zhu, L. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191101124017 · Cited by 24
Nie, X., Kitaoka, S., Shinohara, M., Kakizuka, A., Narumiya, S., & Furuyashiki, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-54082-5 · Cited by 27
Wu, R., Dong, X. Y., Shan, X., Dong, Y. J., & Tao, W. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00022 · Cited by 22
Rubrofusarin Attenuates Chronic Restraint Stress-Induced Depressive Symptoms
Yi, J. H., Jeon, J., Kwon, H., Cho, E., Yun, J., Lee, Y. C., Ryu, J. H., Park, S. J., Cho, J. H., & Kim, D. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103454 · Cited by 18
“Synaptic dysfunctions in the brain of patients with depression were reported [28].”
BackgroundWigner, P., Synowiec, E., Jóźwiak, P., Czarny, P. L., Bijak, M., Barszczewska-Pietraszek, G., Białek, K. I., Szemraj, J., Gruca, P., Papp, M., et al. (2020) · Genes · doi:10.3390/genes11060644 · Cited by 22
“Long-term exposure to free radicals may consequently cause cell death as well as neuronal and glia atrophy, leading to a decreased volume of gray matter and reduced number of cells observed in depressed patients [66,67].”
BackgroundNeurobiological and psychological factors to depression
Turner, M. (2024) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2024.2382091 · Cited by 28
“Glucocorticoid imbalances results in extended autonomic and neuroendocrine disturbances (Drevets et al., 2008), observed across more than 50% of MDD patients (Duman & Aghajanian, 2012).”
Wang, H., Zhao, Q., Zhang, Y., Ma, J., Lei, M., Zhang, Z., Xue, H., Liu, J., Sun, Z., Xu, J., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111121 · Cited by 22
Dotson, V. M., Gradone, A. M., Bogoian, H. R., Minto, L. R., Taiwo, Z., & Salling, Z. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617721000710 · Cited by 23
“For example, decreased BDNF expression and signaling result in reduced neuroplasticity associated with neuronal atrophy and reduced synaptic plasticity, particularly in the medial PFC and hippocampus (Diniz et al., 2014; Duman & Aghajanian, 2012).”
BackgroundResearch progress on vesicle cycle and neurological disorders
Zhang, C., Zhu, L., & Chen, C. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31458 · Cited by 18
Gallay, C. C., Forsyth, G., Can, A., Dutton, M., Jamieson, D., Jensen, E., Hermens, D. F., Bennett, M. R., & Lagopoulos, J. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111369 · Cited by 22
Listos, J., Listos, P., Baranowska-Bosiacka, I., Karpiuk, A., Filarowska, J., Łupina, M., Słowik, T., Zawiślak, S., & Kotlińska, J. (2022) · Molecules · doi:10.3390/molecules27082478 · Cited by 20
Liu, H., Zhang, Y., Hou, X., Zhu, C., Yang, Q., Li, K., Fan, L., Zhang, X., Jiang, X., Jin, X., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114822 · Cited by 22
Frank, E., Benabou, M., Bentzley, B., Bianchi, M., Goldstein, T., Konopka, G., Maywood, E., Pritchett, D., Sheaves, B., & Thomas, J. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12600 · Cited by 20
Translating depression biomarkers for improved targeted therapies
Bredt, D. S., Furey, M. L., Chen, G., Lovenberg, T., Drevets, W. C., & Manji, H. K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.013 · Cited by 23
Subcortical biophysical abnormalities in patients with mood disorders
Kumar, A., Yang, S., Ajilore, O., Wu, M., Charlton, R. A., & Lamar, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.84 · Cited by 21
Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Benedetto, B. D., Rupprecht, R., & Czéh, B. (2013) · Current Drug Targets · doi:10.2174/1389450111314110011 · Cited by 24
“Because dysfunctional neuronal connectivity has often been described in MDD patients [3,17], we may hypothesize that dysfunctional glial cells might be involved in the etiopathogenesis of MDD.”
BackgroundIllness severity and biomarkers in depression: Using a unidimensional rating scale to examine BDNF
Caldieraro, M. A., Vares, E. A., de Souza, L. H., Spanemberg, L., Guerra, T. A., Wollenhaupt-Aguiar, B., Ferrari, P., Nierenberg, A. A., & Fleck, M. P. D. A. (2017) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2017.02.014 · Cited by 22
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders
Haroon, E., & Miller, A. H. (2017) · Modern trends in psychiatry · doi:10.1159/000470805 · Cited by 22
Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission
Lür, G., Fariborzi, M., & Higley, M. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213721 · Cited by 21
Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity
Yaeger, J. D. W., Krupp, K. T., Gale, J., & Summers, C. H. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100059 · Cited by 22
Kühn, M., Maier, J. G., Wolf, E., Mainberger, F., Feige, B., Maywald, S., Bredl, A., Michel, M., Sendelbach, N., Normann, C., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.052 · Cited by 23
Han, Y. S., Lyman, K. A., Clutter, M., Schiltz, G. E., Ismail, Q.-A., Prados, D. B., Luan, C.-H., & Chetkovich, D. M. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115589590 · Cited by 22
“Despite the enormous burden of MDD, antidepressant treatment options—primarily drugs targeting monoaminergic neurotransmitters—have not changed over the past half century.(1) Thus, development of new therapies targeting mechanisms other than monoaminergic pathways could address a major unmet clinical need.”
BackgroundYu, H., Li, M., Shen, X., Lv, D., Sun, X., Wang, J., Gu, X., Hu, J., & Wang, C. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx080 · Cited by 22
“…roles of BDNF and neuropeptide VGF (nonacronymic) in the prefrontal cortex and/or hippocampus in the rapid-acting antidepressant-like actions of ketamine (Li et al., 2010; Duman and Aghajanian, 2012; Voleti et al., 2013; Pazini et al., 2016; Girgenti et al., 2017) and GLYX-13 (Lu et al., 2014).”
BackgroundLiu, S., Zhou, J., Zhu, X., Zhang, Y. L., Zhou, X., Zhang, S., Yang, Z., Wang, Z., Wang, R., Yuan, Y., et al. (2024) · Patterns · doi:10.1016/j.patter.2024.101081 · Cited by 32
“Abnormal functional connectivity in regions such as the precentral gyrus 20 and the hippocampus 57–59 have been found.”
Mitsuhashi, H., Lin, R., Chawla, A., Mechawar, N., Nagy, C., & Turecki, G. (2024) · iScience · doi:10.1016/j.isci.2024.111316 · Cited by 23
Decoding serotonin: the molecular symphony behind depression
Shu, Y. L., Tian, L., Wang, X., Meng, T., Yu, S., & Li, Y. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1572462 · Cited by 28
General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms
Vutskits, L. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002594 · Cited by 25
Zhang, T., Yang, C., Chu, J., Ning, L., Zeng, P. H., Wang, X., Shi, Y., Qin, B., Qu, N., Zhang, Q., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696619 · Cited by 22
Sakai, Y., Li, H., Inaba, H., Funayama, Y., Ishimori, E., Kawatake-Kuno, A., Yamagata, H., Seki, T., Hobara, T., Nakagawa, S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102504 · Cited by 20
“The hippocampus (HPC) is structurally plastic and vulnerable to damage from a variety of psychological stressors (Duman et al., 2019; McEwen, 2001).”
Ahmed, Z. S., Tokhi, A., Arif, M., Rehman, N. U., Sheibani, V., Rauf, K., & Sewell, R. D. E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1135497 · Cited by 19
“, by adapting to the stressor response (Duman and Aghajanian, 2012).”
BackgroundMahmud, A., Avramescu, R. G., Niu, Z., & Flores, C. (2023) · Frontiers in Neural Circuits · doi:10.3389/fncir.2023.1113023 · Cited by 20
“Recent studies highlight the roles of WNT and SHH signaling in depression and depression-like behaviors, possibly via BDNFmediated processes (Voleti and Duman, 2012; Tayyab et al., 2018).”
BackgroundPsilocybin’s Potential Mechanisms in the Treatment of Depression: A Systematic Review
Lee, H. J., Tsang, V. W. L., Chai, B. S., Lin, M. C., Howard, A. K., Uy, C. E., & Elefante, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2223195 · Cited by 22
“Depression has been characterized by neuronal atrophy and impaired neuroplasticity at the molecular level within these areas (Duman and Aghajanian 2012; Duman et al. 2016).”
BackgroundMadjid, N., Lidell, V., Nordvall, G., Lindskog, M., Ögren, S.-O., Forsell, P., & Sandin, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06410-x · Cited by 19
“2007; Hashimoto 2010; Duman and Aghajanian 2012), suggesting that BDNF/TrkB signaling is a part of the therapeutic antidepressant effects.”
BackgroundInfluentialO'Neill, E., Kwok, B., Day, J. S., Connor, T. J., & Harkin, A. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.195 · Cited by 24
“Atrophy and synaptopathy are also observed in psychiatric and mood disorders, such as schizophrenia, autism and depression (Duman and Monteggia 2006; Duman and Aghajanian 2012).”
BackgroundAzogu, I., & Plamondon, H. (2017) · Hormones and Behavior · doi:10.1016/j.yhbeh.2017.02.012 · Cited by 22
“Such evidence has led to the proposed neurotrophic hypothesis of depression (Duman, 2004; Duman and Aghajanian, 2012; Duman and Li, 2012; Duman and Voleti, 2012; Hosang et al., 2014), particularly suited to depressive disorders developing from stress exposure (Chao, 2003).”
Zhang, M., Li, R., Wang, Y., & Huang, Z. (2017) · Neural Plasticity · doi:10.1155/2017/5870735 · Cited by 23
“Studies using rodent models revealed that stress can lead to atrophy and loss of neurons and glia in the PFC and hippocampus [88, 89], which is consistent with a decrease in synapse number in the PFC of patients with depression as demonstrated in postmortem studies [90].”
MethodLi, Y., Huang, P., Guo, T., Guan, X., Gao, T., Sheng, W., Zhou, C., Wu, J., Song, Z., Xuan, M., et al. (2019) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2019.111029 · Cited by 22
Pickering, A. E., & McCabe, C. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12157 · Cited by 21
Karad, V., & Gupta, G. L. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04298-2 · Cited by 23
“Individuals with MDD consistently show decreased BDNF levels in both serum and brain tissue (Duman et al. 2012; Duman et al. 2021).”
Erkizia-Santamaría, I., Horrillo, I., Martínez-Álvarez, N., Pérez-Martínez, D., Rivero, G., Erdozain, A. M., Meana, J. J., & Ortega, J. E. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03421-4 · Cited by 26
“HPA impairment negatively affects different brain areas involved in mood regulation, such as the prefrontal cortex (PFC) [18].”
Therapeutic Implications of microRNAs in Depressive Disorders: A Review
Hassan, M., Amir, A., Shahzadi, S., & Kloczkowski, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113530 · Cited by 24
“The synaptic plasticity is also involved in decrease or loss of neurotrophic factors (NTFs), disturbance of estradiol cycle, and increased levels of inflammatory cytokines which are ultimately causes of depression [13].”
BackgroundZarebavani, M., Naeini, F. B., Farahvash, A., Moradi, F., & Dashti, N. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23311 · Cited by 23
The role of GPR39 zinc receptor in the modulation of glutamatergic and GABAergic transmission
Starowicz, G., Siodłak, D., Nowak, G., & Młyniec, K. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00478-0 · Cited by 19
“Further research focused on ketamine, brain-derived neurotrophic factor (BDNF), and the role of neuroplasticity on the pathomechanism of depression, seemed to contradict the model of inhibition of glutamatergic signaling; this suggested the activation of glutamatergic transmission as the key mechanism behind the rapid…”
BackgroundQian, X., Zhong, Z.-D., Zhang, Y., Qiu, L., & Tan, H.-J. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148723 · Cited by 19
Glasgow, N. G., & Johnson, J. W. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1096-0_2 · Cited by 21
“Memantine along with another NMDAR open channel blocker, ketamine, have shown promise in the treatment of several other debilitating nervous system disorders (4-7,14,15).”
BackgroundGuo, F., Zhang, B., Fu, Z., Ma, Y., Gao, Y., Shen, F., Huang, C., & Li, Y. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.006 · Cited by 19
“Moreover, these dysfunctions can be reversed by the administration of certain antidepressants (Duman and Aghajanian, 2012; Pittenger and Duman, 2007).”
BackgroundDisruption of Ninjurin1 Leads to Repetitive and Anxiety-Like Behaviors in Mice
Le, H.-A., Ahn, B., Lee, H., Shin, A., Chae, S., Lee, S.-Y., Shin, M., Lee, E.-J., Cha, J.-H., Son, T., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0207-6 · Cited by 20
Optogenetic Control of Spine-Head JNK Reveals a Role in Dendritic Spine Regression
Hollós, P., John, J., Lehtonen, J. V., & Coffey, E. T. (2020) · eNeuro · doi:10.1523/eneuro.0303-19.2019 · Cited by 23
“…2015; Varidaki et al., 2016; Wohleb et al., 2018), and postmortem studies report that there are spine deficits in prefrontal cortex and hippocampus of these individuals (Michelsen et al., 2007; Duman, 2009; Hajszan et al., 2009; Duman et al., 2012; Duman and Aghajanian, 2012; Radley et al., 2013).”
Background(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Chen, Y., Xie, S.-Y., Chen, C., & Lu, D. (2021) · Molecular Brain · doi:10.1186/s13041-021-00860-0 · Cited by 27
Stan, T. L., Sousa, V. C., Zhang, X., Ono, M., & Svenningsson, P. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.007 · Cited by 18
“It has, indeed, been shown that NMDAR antagonists, including ketamine and Ro25-6981, have rapid and sustained antidepressive effects in both clinical and pre-clinical settings (Autry et al., 2011; Duman and Aghajanian, 2012; Kiselycznyk et al., 2015; Kiselycznyk et al., 2011; Li et al., 2010; Maeng et al., 2008; Zarat…”
BackgroundAllopregnanolone increases mature excitatory synapses along dendrites via protein kinase A signaling
Shimizu, H., Ishizuka, Y., Yamazaki, H., & Shirao, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.079 · Cited by 20
Effect of Sirtuin-1 on Synaptic Plasticity in Nucleus Accumbens in a Rat Model of Heroin Addiction
Xia, B., Li, Y., Strochlic, T., Yin, D., Chen, X., Li, J., & Wenmei, L. (2018) · Medical Science Monitor · doi:10.12659/msm.910550 · Cited by 18
“Postsynaptic density protein-95 (PSD-95) plays a key role in the signal transduction underlying synaptic plasticity [34,35], and is critical for the generation and maintenance of LTP [36].”
Zhang, K., He, M.-Y., Su, D., Pan, X., Li, Y., Zhang, H., Yang, J., & Wu, C. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.11.020 · Cited by 19
Are 24-hour motor activity patterns associated with continued rapid response to ketamine?
Duncan Jr, W. C., Slonena, E. E., Hejazi, N. S., Brutsche, N., Park, L. T., Henter, I. D., Ballard, E. D., & Zarate Jr, C. A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s172089 · Cited by 17
Lyman, K. A., Han, Y., Zhou, C., Renteria, I., Besing, G.-L., Kurz, J. E., & Chetkovich, D. M. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abl4580 · Cited by 17
“There is an increasing recognition of the importance of excitatory neurotransmission in MDD and antidepressant efficacy (1, 71, 72).”
BackgroundAltered synaptic homeostasis: a key factor in the pathophysiology of depression
Wang, B., He, T., Qiu, G., Li, C., Xue, S., Zheng, Y., Wang, T., Xia, Y., Yao, L., Yan, J., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01369-y · Cited by 21
“It has been proposed that depression may stem from disruptions in the homeostatic mechanisms regulating synaptic plasticity [15].”
Ren, B., Yuan, Q., Cha, S., Liu, S.-Y. M., Zhang, J., & Guo, G. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05152-5 · Cited by 26
“…changes of long-term potentiation (LTP) or long-term depression (LTD) in synaptic strength and connectivity, suggesting disrupted synaptic plasticity (reviewed in [16]); (3) synaptic loss and dendritic spine remodeling representing disrupted structural plasticity (reviewed in [13, 17, 18]).”
Chen, S.-J., Gao, C., Lv, Q., Zhao, M.-Q., Qin, X., & Liao, H. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00823-0 · Cited by 19
“Aberrant synapse structure and number tend to impair synaptic plasticity and neural circuits between different brain areas of the limbic system, and are responsible for depression symptoms [56, 57].”
BackgroundDFO treatment protects against depression-like behaviors and cognitive impairment in CUMS mice
Zhang, W., Yu, M., Zhang, Q., Yang, Z. R., & Zhang, T. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.06.016 · Cited by 23
Yan, A. L., Liu, C., Xu, S. L., Qian, Y., Song, P., Wei, M., & Liu, B. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14030 · Cited by 17
Chen, K., Qi, X., Zhu, L., Li, M., Cong, B., & Li, Y. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110861 · Cited by 18
“Severe stress can affect the structure and function of vital organs, especially the brain (Duman and Aghajanian, 2012), cause psychological and cognitive dysfunction, and promote the occurrence and development of neurodegenerative diseases such as Parkinson ’ s disease and Alzheimer ’ s disease…”
BackgroundTang, Y.-N., Yu, X., Zhang, X., Xia, W., Wu, X., Zou, X., Li, H., Huang, X., Stefan, H., Chen, Q., et al. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.039 · Cited by 18
“Second, increasing histopathological and neuroimaging evidence from monkey and human studies has demonstrated that anesthetics induce neurotoxicity and neuroplasticity (Vincent et al., 2007; Duman and Aghajanian, 2012; Jevtovic-Todorovic et al., 2013; Abdallah et al., 2014).”
BackgroundDrug testing physicians for substances of abuse: case report of a false-positive result
Fitzsimons, M. G., Ishizawa, Y., & Baker, K. H. (2013) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2013.05.009 · Cited by 19
“The current authors point out that ketamine has been used for management of depression, so a medical use is emerging.(1)”
Mania following ketamine abuse
Lane, H., Lu, Y., & Lin, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s97696 · Cited by 22
“Acute changes in cortical excitability and glutamate release are proposed to initiate a sequence of biochemical and structural changes within cortical networks.(8,9) The abnormality may occur in people with bipolar tendency, whose glutamate receptors are hypersensitive or glutamate is overreleasing.”
BackgroundYang, B., Qin, J., Nie, Y., & Chen, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6876 · Cited by 19
“…target of rapamycin (p-mTOR) signaling are implicated in the mechanisms underlying the antidepressant action of the NMDA receptor antagonists (11,14,15), western blot analysis was performed to examine the effects of MK-801 and rapastinel on the protein expression of BDNF, GluA1 and p-mTOR in…”
Wang, J., Wang, Y., Gao, T., Liu, L., Wang, Y., Guan, W., Chen, T., Zhao, J., Zhang, Y., & Jiang, B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.096 · Cited by 17
LIMK1/2 in the mPFC Plays a Role in Chronic Stress-Induced Depressive-Like Effects in Mice
Gao, T., Wang, Y., Liu, L., Wang, J., Wang, Y., Guan, W., Chen, T., Zhao, J., & Jiang, B. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa067 · Cited by 18
“Defects in neurite formation and morphogenesis can cause neurological disorders, and it has been demonstrated that depression is associated with atrophy of neurons and reduced connectivity (Duman and Aghajanian, 2012; Qiao et al., 2016; Duman et al., 2019).”
BackgroundChen, L., Gong, W., Yang, C., Shao, C.-C., Song, N., Chen, J., Zhou, L., Zhang, K., Li, S., Huang, Z., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01303-z · Cited by 18
NMDAR Neurotransmission Needed for Persistent Neuronal Firing: Potential Roles in Mental Disorders
Yang, S., Seo, H., Wang, M., & Arnsten, A. F. T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.654322 · Cited by 20
Dong, C., Tian, Z. R., Fujita, Y., Fujita, A., Hino, N., Iijima, M., & Hashimoto, K. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173316 · Cited by 18
Ketamine: A Review for Clinicians
Sanacora, G., & Katz, R. R. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180012 · Cited by 21
“Although the monoamine-based antidepressants alter synaptic plasticity (11, 12), the effects are subtle and seen only after prolonged exposure.”
BackgroundThe emerging landscape of brain glycosylation: from molecular complexity to therapeutic potential
Seo, Y., Park, J. E., Yu, J. Y., Lee, B., Yoon, J. H., & An, H. J. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01560-8 · Cited by 23
“…neurotransmitter pathways (for example, glutamatergic, γ -aminobutyric acid (GABA)ergic and dopaminergic), neurotrophic factor signaling and synaptic plasticity mechanisms, underlies a wide spectrum of brain diseases, including neurodegenerative, neurodevelopmental and psychiatric disorders 4 – 6 .”
Rapid Antidepressant Activity of Ketamine Beyond NMDA Receptor
Hashimoto, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_4 · Cited by 17
Zhang, J., Liu, Y., Li, L.-X., Li, K., Chen, J., & Wang, F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107934 · Cited by 16
Antidepressant chronotherapeutics normalizes prefrontal 1H-MRS glutamate in bipolar depression
Melloni, E. M. T., Bravi, B., Poletti, S., Dallaspezia, S., Barbini, B., Zanardi, R., & Benedetti, F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110606 · Cited by 17
Shao, X., Yan, D., Kong, W., Sun, S., Liao, M., Ou, W., Zhang, Y., Zheng, F., Li, X., Li, L., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115072 · Cited by 18
Yin, Y., Zhu, Y., Liu, J., Fan, Q.-C., Wu, X., Zhao, S., Wang, J., Liu, Y., Li, Y., & Lu, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14438 · Cited by 18
Fang, Y., Li, Y., Liao, X. D., Deng, J., Wang, Q., Liang, J., & Yan, B. (2023) · Journal of Medicinal Food · doi:10.1089/jmf.2023.k.0050 · Cited by 17
“10,11 12–14 The chronic unpredictable mild stress (CUMS)-induced depression model has been widely used to screen antidepressants.”
Pathogenesis of Depression in Alzheimer’s Disease
Zhan, Q., Kong, F., Shao, S., Zhang, B., & Huang, S.-M. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04061-0 · Cited by 20
“Studies have shown that both animal models and individuals with depression experience a significant decrease in hippocampal volume and the number of hippocampal granule neurons (GNs) [114, 115], a phenomenon that can be reversed through treatment with SSRIs [116].”
Sikirić, P., Blagaić, A. B., Štrbe, S., Orešković, L. B., Orešković, I., Sikirić, S., Starešinić, M., Sever, M., Kokot, A., Jurjević, I., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17040461 · Cited by 19
“Refractory anxiety may cause glutamate receptor damage in the hippocampus and neuronal atrophy in the prefrontal cortex (PFC), which can result in mood disturbances and cognitive deficits [205].”
BackgroundGuo, F., Zhang, B., Shen, F., Li, Q., Song, Y., Li, T., Zhang, Y.-M., Du, W., Li, Y., Liu, W., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16420 · Cited by 17
“NMDARs have been considered to be a potential target for the treat-ment of depression (Autry et al., 2011; Duman & Aghajanian, 2012).”
Loria, M. J., White, S. W., Robbins, S. A., Salmeto, A. L., Hymel, K. A., Murthy, S. N., Manda, P., & Sufka, K. J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.045 · Cited by 16
“Recent studies suggest alterations in neurotrophins, particularly brainderived neurotrophic factor (BDNF), play an important role in the pathogenesis of MDD and treatment outcomes [4–6].”
BackgroundTarai, S., Mukherjee, R., Gupta, S., Rizvanov, A. A., Palotás, A., Pammi, V. S. C., & Bit, A. (2019) · Cognitive Neurodynamics · doi:10.1007/s11571-019-09522-3 · Cited by 18
Eldomiaty, M. A., Makarenko, O., Hassan, Z. A., Almasry, S. M., Petrov, P., & Elnaggar, A. M. (2020) · Folia Morphologica · doi:10.5603/fm.a2020.0007 · Cited by 16
PET Imaging of Synaptic Vesicle Protein 2A
Finnema, S. J., Li, S., Cai, Z., Naganawa, M., Chen, M.-K., Matuskey, D., Nabulsi, N., Esterlis, I., Holmes, S. E., Radhakrishnan, R., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_29 · Cited by 21
Antidepressant Actions of Ketamine: Potential Role of L-Type Calcium Channels
Robinson, B. L., Gu, Q., & Kanungo, J. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00411 · Cited by 18
Biobehavioral correlates of an fMRI index of striatal tissue iron in depressed patients
Price, R. B., Tervo‐Clemmens, B., Panny, B., Degutis, M., Griffo, A., & Woody, M. L. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01553-x · Cited by 22
Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
Kowalczyk, M., Kowalczyk, E., Kwiatkowski, P. A., Łopusiewicz, Ł., Sienkiewicz, M., & Talarowska, M. E. (2021) · Life · doi:10.3390/life11111186 · Cited by 18
Liu, C., Yang, T., Zhou, Y., & Shen, Y. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136766 · Cited by 18
“Decreased neuronal synapse in functional connectivity in the brain regions that regulate mood and cognition are hypothesized to contribute to symptoms associated with MDD [7].”
BackgroundJung, J., Loy, K., Schilling, E.-M., Röther, M., Brauner, J. M., Huth, T., Schlötzer-Schrehardt, U., Alzheimer, C., Kornhuber, J., Welzel, O., et al. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8569-5 · Cited by 10
“The authors of this study could show that ketamine induced synaptogenesis and an amelioration of synaptic function [4], and thus pointing out the importance of synaptic transmission in major depressive disorder (MDD), resulting in a “synaptogenic hypothesis” of depression [4].”
BackgroundQi, C., Shu, Y., Chen, F.-H., Ding, Y., & Zhou, J. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.12.009 · Cited by 18
Rough-and-tumble play induces resilience to stress in rats
Burgdorf, J. S., Kroes, R. A., & Moskal, J. R. (2017) · Neuroreport · doi:10.1097/wnr.0000000000000864 · Cited by 20
Zhao, J., Lao, L., Cui, W., & Rong, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1610-5 · Cited by 15
“found that depression caused the neuronal atrophy and reduced the synaptic connections in the cortex [4].”
Nitrous Oxide Induces Prominent Cell Proliferation in Adult Rat Hippocampal Dentate Gyrus
Chamaa, F., Bahmad, H. F., Makkawi, A.-K., Chalhoub, R., Al–Chaer, E. D., Bikhazi, G. B., Nahas, Z. H., & Abou-Kheir, W. G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00135 · Cited by 17
“Accumulating evidences put forward an increased association of N-methyl-D-aspartic acid (NMDA) receptor signaling with the neurobiology of depression (Li et al., 2010; Autry et al., 2011; Duman and Aghajanian, 2012).”
BackgroundBrain matrix metalloproteinase-9 activity is altered in the corticosterone mouse model of depression
Breviario, S., Senserrich, J., Florensa-Zanuy, E., Garro-Martínez, E., Díaz, Á., Castro, E., Pazos, Á., & Pilar-Cuéllar, F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110624 · Cited by 18
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions
Onisiforou, A., Georgiou, P., & Zanos, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173531 · Cited by 12
Ge, J., Tan, R., Gao, Q., Li, R., Xu, P., Song, H., Wang, S., Wan, Y., & Zhou, L. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300154 · Cited by 18
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.